Acurion Closes $4.3M Seed Round for AI-Powered Precision Oncology Platform
Precision in oncology has always been a timing problem dressed up as a data problem. Acurion just raised $4.3M in seed funding, and instead of adding more noise to the system, they are tightening the signal to the point where decisions can finally keep pace with disease.
San Diego keeps doing what San Diego does, quietly stacking biotech hitters while everyone else argues on panels. Acurion steps in with OncoGaze, an AI-driven platform that pulls clinically actionable biomarkers straight from routine pathology slides. No extra hoops, no waiting weeks for sequencing. Just insight, fast enough to matter when time is the only currency patients cannot refinance.
TK & Partners led the round, with Mesa Verde Venture Partners, The National Foundation for Cancer Research, Asian Fund for Cancer Research, and Bootstrap Ventures all leaning in. Oversubscribed too, which is investor-speak for we tried to keep it tight and the room kept getting crowded anyway. Smart money tends to recognize when physics meets software in a way that actually changes outcomes.
Credit where it is due. Rick Fultz steering as CEO, Ludmil B. Alexandrov, Ph.D. building as CTO and co-founder, and Magda Marquet, Ph.D. as co-founder bringing that pattern recognition you only get from living through multiple cycles. Add Feng Cao, Ph.D. as COO, and you start to see the architecture behind the ambition. This is not a science project. This is a system.
The play here is subtle but sharp. Nearly 100 precision oncology therapies exist, yet fewer than 1 in 20 patients receive them. That gap is not a science problem, it is an access problem disguised as complexity. Acurion is betting that if you make insight instantaneous and embed it into workflows that already exist, adoption stops being a fight and starts being inevitable.
OncoGaze does not ask clinicians to change behavior. It meets them where they already are, inside standard pathology. That is the kind of restraint that wins markets. Not louder. Not flashier. Just friction removed at exactly the right moment.
This capital goes toward clinical validation, platform development, and the unglamorous but essential march toward regulatory readiness and commercialization. Translation: turning something impressive into something indispensable. There is a rhythm to breakthroughs like this. First the science whispers. Then the data starts to hum. Then capital shows up, not to gamble, but to accelerate what already feels inevitable.
